Form 4: Neurocrine Biosciences Chief Medical Officer Exercises Stock Options

Neurocrine Biosciences' Chief Medical Officer, Eiry Roberts, exercised stock options, acquiring a total of 7,345 shares of common stock at various prices.

Summary

• Eiry Roberts, Chief Medical Officer of Neurocrine Biosciences, exercised stock options on November 8, 2024.
• The transactions involved the acquisition of 7,345 shares of common stock through the exercise of incentive stock options.
• The exercise prices ranged from $77.81 to $102.9 per share.
• Following these transactions, Dr. Roberts directly owns 31,061 shares of Neurocrine Biosciences common stock.
• Additionally, 29,876 shares are held by The Stephen Tayor and Eiry W. Roberts Joint Trust Agreement, where Dr. Roberts has voting and investment power.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction of stock option exercises by a company executive, which is generally viewed as neutral to slightly positive as it indicates confidence in the company's future.

Positives

• The exercise of stock options by a key executive suggests confidence in the company's future performance.
• The acquisition of shares at various prices indicates a long-term investment perspective by the executive.

Industry Context

This is a routine filing related to executive stock option exercises, which is common in the biotechnology industry as part of compensation packages.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedules described are typical for incentive stock options, with gradual vesting over several years.
• The prices at which the options were exercised are within the range of the company's stock price during the relevant periods.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it indicates executive confidence in the company.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

stock options, insider trading, executive compensation, Neurocrine Biosciences, NBIX, Eiry Roberts, Chief Medical Officer, share acquisition